Chinese medical journal pulmonary and critical care medicine最新文献

{"title":"Clinical characteristics of patients with positive fungal pathogens during acute exacerbation of chronic obstructive pulmonary disease: A retrospective study","authors":"Lijuan Luo ,&nbsp;Lijun Liu ,&nbsp;Yiming Ma ,&nbsp;Herui Li ,&nbsp;Zihang Zeng ,&nbsp;Yan Chen","doi":"10.1016/j.pccm.2025.02.007","DOIUrl":"10.1016/j.pccm.2025.02.007","url":null,"abstract":"<div><h3>Background</h3><div>Fungal infections in acute exacerbation of chronic obstructive pulmonary disease (AECOPD) patients are poorly understood and often result in a poor prognosis. This study aimed to investigate the distribution of common fungi and the clinical features of AECOPD patients positive for fungal pathogens.</div></div><div><h3>Methods</h3><div>Data were collected from inpatients with AECOPD at the Second Xiangya Hospital of Central South University from January 2016 to December 2019. The enrolled patients were divided into an infection group and a colonization group, and clinical data were compared between the two groups. A 1:1 propensity score matching (PSM) process was employed to ensure balanced samples to analyze the impact of positive fungal pathogens on the clinical features of AECOPD patients. The incidence of acute exacerbations one year after discharge was determined via telephone follow-up.</div></div><div><h3>Results</h3><div>The most frequently isolated fungal pathogen was <em>Candida albicans</em> (164/395, 41.5 %), followed by <em>Aspergillus</em> (93/395, 23.5 %). After propensity score matching, 68 patients were equally divided into the infection and colonization groups. There was no significant difference in clinical manifestations between the infection and colonization groups (<em>P</em> &gt; 0.05). Patients in the infection group had significantly higher procalcitonin (PCT) values (0.2 [0.1, 0.7] ng/ml <em>vs</em>. 0.1 [0, 0.1] ng/ml; <em>P</em> = 0.003) and lower albumin/globulin ratios (1.1 [0.6, 1.3] <em>vs</em>. 1.1 [1.0, 1.3], <em>P</em> = 0.047) than those in the colonization group. The antibiotic treatment (12.5 [11.0, 19.0] days <em>vs</em>. 10.0 [8.0, 14.0] days; <em>P</em> = 0.002) and hospitalisation duration (18.0 [14.7, 22.5] days <em>vs</em>. 11.0 [8.0, 16.0] days; <em>P</em> &lt; 0.001) in the infection group was significantly longer than that in the colonization group. In addition, more patients in the colonization group received non-invasive mechanical ventilation (76.5 % [26/34] <em>vs</em>. 47.1 % [16/34]; <em>P</em> = 0.013). Compared with the colonization group, more patients in the infection group underwent bronchoscopy (29.4 % [10/34] <em>vs</em>. 2.9 % [1/34]; <em>P</em> = 0.003). Using multivariable analysis, we found that bronchoscopy (OR: 1.350, 95 % CI: 1.020–1.771, <em>P</em> = 0.034) and duration of antibiotics used (OR: 1.318, 95 % CI: 1.090–1.560, <em>P</em> = 0.004) were risk factors for pulmonary fungal infection in AECOPD patients.</div></div><div><h3>Conclusion</h3><div><em>Candida albicans</em> and <em>Aspergillus</em> are the common fungi isolated from patients with AECOPD. The clinical manifestations of AECOPD patients with fungal infection are nonspecific. AECOPD patients with positive fungal isolation who have undergone bronchoscopy and used antibiotics for a longer duration are more likely to have fungal infection.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 111-119"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490256","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crescent jugular dual-lumen catheter for adult veno-venous extracorporeal membrane oxygenation in China: Multicenter initial experience","authors":"Han Zhang ,&nbsp;Gang Liu ,&nbsp;Xiaojun Liu ,&nbsp;Yang Yan ,&nbsp;Xiaozu Liao ,&nbsp;Junmeng Zheng ,&nbsp;Songqiao Liu ,&nbsp;Zhen Guo ,&nbsp;Jian Rong ,&nbsp;Fangqiang Song ,&nbsp;Chunyao Wang ,&nbsp;Zan Chen ,&nbsp;Chengbin Zhou ,&nbsp;Man Huang ,&nbsp;Bingyang Ji","doi":"10.1016/j.pccm.2025.05.003","DOIUrl":"10.1016/j.pccm.2025.05.003","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 141-143"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490286","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Achieving remission in severe asthma","authors":"Sarita Thawanaphong ,&nbsp;Santi Nolasco ,&nbsp;Parameswaran Nair","doi":"10.1016/j.pccm.2025.05.001","DOIUrl":"10.1016/j.pccm.2025.05.001","url":null,"abstract":"<div><div>Severe asthma affects 5–10 % of asthma patients worldwide, imposing a significant burden due to an increased risk of mortality, impaired quality of life, and substantial economic costs. Recent advancements in biologic therapies have transformed asthma management by targeting specific inflammatory pathways, particularly type 2 inflammation. Biologic treatments such as omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab have demonstrated efficacy in reducing exacerbations, improving lung function, and achieving clinical remission in a subset of patients. This review provides an overview of the mechanisms of action, indications, and treatment efficacy of biologics used in asthma management. We also explore the concept of asthma remission and the potential for achieving it through biologic therapies and complementary strategies, including optimized inhaler use, macrolides, and bronchial thermoplasty. In addition, we discuss how to choose among these treatments wisely and examine the limitations of each biologic therapy. Despite these advancements, clinical remission rates remain modest, underscoring the need for refined patient selection. Emerging tools such as airway biomarkers, proteomics, and advanced imaging techniques offer promising avenues to improve diagnosis and personalize treatment approaches. Future research focused on making advanced biomarkers more accessible and feasible for point-of-care testing will enhance treatment precision. The next step will be integrating a multiomics approach into personalized asthma management for severe disease, further improving asthma control, achieving sustained remission, and ultimately reducing the burden of severe asthma.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 77-87"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sphingolipid metabolism dysregulation: A cause for lung cancer development, progression, and resistance to therapies","authors":"Cungui Mao","doi":"10.1016/j.pccm.2025.05.002","DOIUrl":"10.1016/j.pccm.2025.05.002","url":null,"abstract":"<div><div>Lung cancer remains a leading cause of cancer-related mortality worldwide. Sphingolipids, a diverse class of lipids featuring a sphingoid base backbone, play essential roles in cellular processes and membrane structure. Complex sphingolipids such as sphingomyelins and glycosphingolipids maintain membrane integrity, while their metabolites—ceramide, sphingosine, and their phosphorylated forms, ceramide-1-phosphate (C1P) and sphingosine-1-phosphate (S1P)—act as bioactive lipids involved in regulating key cellular functions. Ceramide and sphingosine are generally tumor-suppressive, promoting apoptosis and inhibiting cell proliferation, whereas C1P and S1P support tumor progression through enhanced cell survival, proliferation, angiogenesis, and metastasis. S1P exerts its effects via G protein-coupled S1P receptors (S1PRs) and intracellular pathways, while C1P acts primarily through intracellular signaling. Dysregulation of these metabolites contributes to lung cancer pathogenesis, influencing tumor survival and resistance to therapy. Targeting sphingolipid metabolism—either by enhancing ceramide and sphingosine levels or inhibiting C1P and S1P—has shown promise in preclinical models. Moreover, these sphingolipid metabolites hold potential as biomarkers for diagnosis and prognosis in lung cancer. This review explores the roles of sphingolipids in lung cancer biology, their impact on tumor progression, and their therapeutic potential.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 88-96"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal trends in the burden of tracheal, bronchial, and lung cancer in China and globally: A comprehensive analysis from 1990 to 2021","authors":"Xue Fan,&nbsp;Linxi Yin,&nbsp;Xuenan Hou,&nbsp;Qing Zhou","doi":"10.1016/j.pccm.2025.04.001","DOIUrl":"10.1016/j.pccm.2025.04.001","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Tracheal, bronchial, and lung (TBL) cancer remains a leading cause of cancer-related deaths globally, with its burden influenced by aging populations, smoking, air pollution, and advances in treatment. China, as one of the most affected countries, faces significant challenges due to rapid industrialization and an aging population. This study aimed to systematically assess the temporal trends and disease burden of tracheal, bronchial, and lung cancer in China from 1990 to 2021, in comparison with global patterns, to provide evidence for targeted prevention and public health policymaking.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;Using data from the Global Burden of Disease (GBD) database (1990–2021), this study analyzed trends in the incidence, prevalence, mortality, and disability-adjusted life years (DALYs) of TBL cancer in China and globally. Joinpoint regression analysis was applied to identify significant changes in trends over time, and the average annual percentage change (AAPC) was calculated to quantify the overall temporal trends. Statistical significance was evaluated using Permutation tests, with results reported as 95 % confidence intervals (95 % CI).&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;In 2021, China accounted for 41.0 % (934,704 of 2,280,688) of global incident cases, 38.8 % (1,262,275 of 3,253,729) of global prevalent cases, 40.4 % (814,364 of 2,016,547) of global deaths, and 40.7 % (18,920,203 of 46,536,272) of global DALYs. The AAPC for China’s age-standardized incidence rate (ASIR), age-standardized prevalence rate (ASPR), age-standardized mortality rate (ASMR), and age-standardized DALYs rate (ASDR) were 0.9 % (95 % CI: 0.8 % to 1.1 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05), 1.8 % (95 % CI: 1.6 % to 2.0 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05), 0.4 % (95 % CI: 0.2 % to 0.6 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05), and 0.1 % (95 % CI: 0.1 % to 2.0 %, &lt;em&gt;P&lt;/em&gt; &gt; 0.05), respectively, while the global AAPCs were −0.3 % (95 % CI: −0.4 % to −0.2 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05), 0.3 % (95 % CI: 0.2 % to 0.4 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05), −0.5 % (95 % CI: −0.7 to −0.4 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05) and −0.9 % (95 % CI: −1.0 % to −0.8 %, &lt;em&gt;P&lt;/em&gt; &lt;em&gt;&lt;&lt;/em&gt; 0.05). Notably, over the last two decades, the growth rate of China’s ASIR has slowed, the ASMR and ASDR stopped rising and showed a significant decline compared to previous trends. The burden of TBL cancer varied by age and gender; over the past decade, the ASIR, ASMR, and ASDR for males in China have shown a declining trend, whereas the rates for females have increased. Additionally, the peak age of burden has shifted to older age groups compared to 1990.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusion&lt;/h3&gt;&lt;div&gt;China bears a significant share of the global burden of TBL cancer. Over the last two decades, the growth rate of China’s ASIR has slowed, while its ASMR and ASDR have declined, potentially attributable to advancements in targeted therapies and immunotherapies.&lt;/div&gt;&lt;/d","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 120-131"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of chronic obstructive pulmonary disease and risk factors in China from 1990 to 2021: Analysis of global burden of disease 2021","authors":"Fen Dong ,&nbsp;Rui Su ,&nbsp;Yu Ren ,&nbsp;Ting Yang","doi":"10.1016/j.pccm.2025.05.004","DOIUrl":"10.1016/j.pccm.2025.05.004","url":null,"abstract":"&lt;div&gt;&lt;h3&gt;Background&lt;/h3&gt;&lt;div&gt;Chronic obstructive pulmonary disease (COPD) is a common chronic disease that imposes tremendous burdens on the general populations in China and other countries worldwide. A comprehensive understanding of the contemporary epidemiological landscape of COPD is crucial for formulating effective prevention and control strategies. This study was designed to systematically evaluate the temporal trends in COPD burden and its associated risk factors in China over recent decades, providing evidence-based insights for targeted interventions.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Methods&lt;/h3&gt;&lt;div&gt;We conducted a comprehensive analysis of the Global Burden of Disease (GBD) 2021 dataset to systematically evaluate COPD epidemiology in China from 1990 to 2021. Our study quantified key disease burden indicators including incident cases, prevalent cases, deaths, and disability-adjusted life years (DALYs), along with their corresponding crude rates and age-standardized rates, while examining their temporal trends. Furthermore, we stratified these metrics by demographic characteristics (sex and age groups) and assessed the population attributable fractions of major risk factors for COPD in the Chinese population.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Results&lt;/h3&gt;&lt;div&gt;In 2021, China had an estimated 4.43 (95 % uncertainty interval [UI]: 4.01–4.86) million incident COPD cases and 50.59 (95 % UI: 44.98–57.12) million prevalent cases, accounting for nearly one-quarter of COPD prevalent cases worldwide. The crude COPD incidence and prevalence rates in China were 311.68 (95% UI: 281.75–341.62) per 100,000 and 3555.69 (95% UI: 3161.20–4014.55) per 100,000, respectively. Nearly 1.29 (95 % UI: 1.04–1.54) million individuals died from COPD, representing 10.99 % of deaths in China, and the crude mortality rate was 90.35 (95 % UI: 73.43–108.23) per 100,000. The DALYs were estimated at 23.64 (95 % UI: 20.00–27.92) million person years and the crude DALYs rate was 1661.60 (95 % UI: 1405.64–1962.54) per 100,000. The age-specific COPD incidence and prevalence rates increased substantially at 40 years of age and continued to rise thereafter. The mortality and DALY rates increased tremendously in elderly population. Sex disparities existed in the mortality and DALY rates, with both being markedly higher in men than in women, particularly among older adults aged &gt;60 years, indicating non-optimal disease management in this population subgroup. Smoking was the leading risk factor for COPD deaths and DALYs, followed by particulate matter pollution and occupational exposure. The age-standardized rates for all metrics decreased substantially from 1990 to 2021, especially the mortality and DALY rates with decreases of 68.40 % and 68.13 %, respectively. Nevertheless, the numbers of incident and prevalent COPD cases increased, with both having doubled in 2021 compared with those in 1990.&lt;/div&gt;&lt;/div&gt;&lt;div&gt;&lt;h3&gt;Conclusions&lt;/h3&gt;&lt;div&gt;While the age-standardized rates for COPD incidence, prevalence, mort","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 132-140"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"I-125 brachytherapy for early-stage non-small cell lung cancer","authors":"Leilei Shi,&nbsp;Nansheng Wan,&nbsp;Guangsheng Li,&nbsp;Yubao Wang,&nbsp;Jing Feng","doi":"10.1016/j.pccm.2025.05.006","DOIUrl":"10.1016/j.pccm.2025.05.006","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 97-99"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Burden of chronic respiratory diseases and their attributable risk factors in 204 countries and territories, 1990–2021: Results from the global burden of disease study 2021","authors":"Zhong Cao ,&nbsp;Liu He ,&nbsp;Yuheng Luo ,&nbsp;Xunliang Tong ,&nbsp;Jinghan Zhao ,&nbsp;Ke Huang ,&nbsp;Qiushi Chen ,&nbsp;Lirui Jiao ,&nbsp;Yuhao Liu ,&nbsp;Pascal Geldsetzer ,&nbsp;Ting Yang ,&nbsp;Chen Wang ,&nbsp;Till Winfried Bärnighausen ,&nbsp;Simiao Chen","doi":"10.1016/j.pccm.2025.05.005","DOIUrl":"10.1016/j.pccm.2025.05.005","url":null,"abstract":"<div><h3>Background</h3><div>Chronic respiratory diseases (CRDs) remain a substantial global public health challenge, contributing significantly to morbidity and mortality worldwide. This study aimed to comprehensively characterize trends in CRD burden across various populations by examining differences by sex, age, and sociodemographic index (SDI).</div></div><div><h3>Methods</h3><div>We performed a systematic analysis using data from the Global Burden of Disease (GBD) 2021 study, covering the period from 1990 to 2021 across 204 countries and territories. Estimates of age-standardized prevalence, mortality, disability-adjusted life years (DALYs), incidence, and annualized percentage changes for both 1990–2021 and 2019–2021 were calculated. Geographic and demographic variations were evaluated by age, sex, and SDI. The contributions of key risk factors—including tobacco use, ambient particulate matter (PM) pollution, household air pollution from solid fuels, and occupational exposure to PM, gases, and fumes—were also assessed.</div></div><div><h3>Results</h3><div>In 2021, an estimated 468.3 million individuals globally were living with CRDs, with an age-standardized prevalence rate of 5785.4 per 100,000 population. CRDs accounted for 4.4 million deaths with age-standardized mortality rate of 53.6 per 100,000 population and 108.5 million DALYs with age-standardized DALY rate of 1294.6 per 100,000 population in the same year. Age-standardized prevalence rate decreased by 1.01 % from 1990 to 2021 but increased by 0.20 % from 2019 to 2021. From 2019 to 2021, the age-standardized incidence rate of CRDs increased slightly from 713.4 to 719.3 per 100,000 population, with an annualized percentage change of 0.41 %, while the age-standardized DALY rate continued to decline from 1321.9 to 1294.6 per 100,000 population, with an annualized percentage change of −1.04 %. Although the age-standardized mortality rate declined by 1.46 % over the full period, the absolute number of deaths rose as a result of demographic shifts, including population growth and aging. Globally, tobacco use remained the predominant risk factor, while household air pollution from solid fuels was the leading contributor to DALYs and mortality in low- and low-middle SDI countries.</div></div><div><h3>Conclusion</h3><div>The global burden of CRDs remains both substantial and dynamic, underscoring the continued influence of risk factors such as tobacco use and household air pollution. These findings emphasize the urgent need for targeted public health interventions and more equitable healthcare resource allocation, particularly in low- and middle-SDI regions. Strengthened surveillance systems, improved access to care, and integrated strategies addressing both established and emerging risk factors are essential for reducing the global impact of CRDs.</div></div>","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 2","pages":"Pages 100-110"},"PeriodicalIF":0.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144490255","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “Quan M, Guo Q, Yan X, et al. Parkin deficiency aggravates inflammation-induced acute lung injury by promoting necroptosis in alveolar type II cells” [Chin Med J Pulm Crit Care Med 2024;2:265-278]","authors":"","doi":"10.1016/j.pccm.2025.01.002","DOIUrl":"10.1016/j.pccm.2025.01.002","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 1","pages":"Page 63"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Guide for Authors","authors":"","doi":"10.1016/S2772-5588(25)00018-0","DOIUrl":"10.1016/S2772-5588(25)00018-0","url":null,"abstract":"","PeriodicalId":72583,"journal":{"name":"Chinese medical journal pulmonary and critical care medicine","volume":"3 1","pages":"Pages 66-76"},"PeriodicalIF":0.0,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143715472","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}